318160 — Cell Bio Human Tech Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩34bn
- KR₩24bn
- KR₩27bn
- 65
- 79
- 18
- 56
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 24,103 | 28,588 | 35,161 | 27,545 | 27,324 |
Cost of Revenue | |||||
Gross Profit | 8,920 | 9,949 | 10,225 | 7,643 | 7,729 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 19,419 | 23,313 | 29,837 | 24,442 | 24,548 |
Operating Profit | 4,684 | 5,276 | 5,324 | 3,103 | 2,777 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,960 | 4,789 | 4,479 | 3,541 | -812 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4,454 | 4,215 | 3,113 | 2,890 | -1,857 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 4,505 | 4,187 | 3,131 | 2,890 | -1,857 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 4,505 | 3,776 | 2,824 | 2,890 | -1,857 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 590 | 488 | 399 | 421 | -174 |
Dividends per Share |